MRNA is trading up 3.05% at $44.31 following the announcement of positive five-year follow-up data for its intismeran autogene combined with Keytruda in high-risk melanoma patients.
- The data demonstrated a 49% lower risk of cancer recurrence or death compared to Keytruda alone, reinforcing the company's oncology pivot.
- Bank of America raised its price target to $27 (from $24) but maintained an Underperform rating, citing increased sales expectations despite acknowledging a higher bar for success.
- Phase 3 melanoma data and results from eight ongoing cancer studies are expected in 2026, aligning with Moderna's broader pipeline expansion.